ES2123432A1 - Formulation for oral delivery of iron complexes - comprises water-soluble adduct comprising polyhydroxylated trivalent iron complex with soluble albumin - Google Patents
Formulation for oral delivery of iron complexes - comprises water-soluble adduct comprising polyhydroxylated trivalent iron complex with soluble albuminInfo
- Publication number
- ES2123432A1 ES2123432A1 ES9602180A ES9602180A ES2123432A1 ES 2123432 A1 ES2123432 A1 ES 2123432A1 ES 9602180 A ES9602180 A ES 9602180A ES 9602180 A ES9602180 A ES 9602180A ES 2123432 A1 ES2123432 A1 ES 2123432A1
- Authority
- ES
- Spain
- Prior art keywords
- soluble
- polyhydroxylated
- albumin
- adduct
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Water-soluble adduct comprises polyhydroxylated trivalent iron complex with soluble desensitised albumin. The polyhydroxylated compound comprises a compound containing more than one hydroxyl group and capable of forming complexes with trivalent iron. The albumin has been subjected to finish treatment, alkali treatment and oxidation by solubilisation without affecting its molecular weight. The adduct is obtained by mixing the iron complex solution with the treated albumin solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9602180A ES2123432B1 (en) | 1996-10-15 | 1996-10-15 | TRIVALENT IRON POLYHYDROXYLATED COMPLEX ADDUCTS WITH SOLUBLE ALBUMINE, METHOD OF OBTAINING, AND PHARMACEUTICAL AND DIETARY PREPARATIONS CONTAINING THEM. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9602180A ES2123432B1 (en) | 1996-10-15 | 1996-10-15 | TRIVALENT IRON POLYHYDROXYLATED COMPLEX ADDUCTS WITH SOLUBLE ALBUMINE, METHOD OF OBTAINING, AND PHARMACEUTICAL AND DIETARY PREPARATIONS CONTAINING THEM. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2123432A1 true ES2123432A1 (en) | 1999-01-01 |
ES2123432B1 ES2123432B1 (en) | 1999-10-01 |
Family
ID=8296371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES9602180A Expired - Fee Related ES2123432B1 (en) | 1996-10-15 | 1996-10-15 | TRIVALENT IRON POLYHYDROXYLATED COMPLEX ADDUCTS WITH SOLUBLE ALBUMINE, METHOD OF OBTAINING, AND PHARMACEUTICAL AND DIETARY PREPARATIONS CONTAINING THEM. |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2123432B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2188336A1 (en) * | 2000-10-18 | 2003-06-16 | Tedec Meiji Farma S A | Soluble albumin adducts with polyhydroxilated complexes (polyalcoholic) of trivalent iron, method for obtaining them and pharmaceutical and dietetic preparations that contain them. |
EP1655308A1 (en) | 2004-11-03 | 2006-05-10 | Tedec-Meiji Farma, S.A. | Adducts of soluble ovalbumin with trivalent iron polyalcohol complexes and method to produce them |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0304183A1 (en) * | 1987-08-20 | 1989-02-22 | Biomedical Frontiers, Inc. | Stabilization of deferoxamine to chelate free ions in physiological fluid |
WO1990001295A1 (en) * | 1988-08-04 | 1990-02-22 | Advanced Magnetics, Incorporated | Receptor mediated endocytosis type mri contrast agents |
-
1996
- 1996-10-15 ES ES9602180A patent/ES2123432B1/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0304183A1 (en) * | 1987-08-20 | 1989-02-22 | Biomedical Frontiers, Inc. | Stabilization of deferoxamine to chelate free ions in physiological fluid |
WO1990001295A1 (en) * | 1988-08-04 | 1990-02-22 | Advanced Magnetics, Incorporated | Receptor mediated endocytosis type mri contrast agents |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2188336A1 (en) * | 2000-10-18 | 2003-06-16 | Tedec Meiji Farma S A | Soluble albumin adducts with polyhydroxilated complexes (polyalcoholic) of trivalent iron, method for obtaining them and pharmaceutical and dietetic preparations that contain them. |
EP1655308A1 (en) | 2004-11-03 | 2006-05-10 | Tedec-Meiji Farma, S.A. | Adducts of soluble ovalbumin with trivalent iron polyalcohol complexes and method to produce them |
ES2258391A1 (en) * | 2004-11-03 | 2006-08-16 | Tedec-Meiji Farma, S.A. | Adducts of soluble ovalbumin with trivalent iron polyalcohol complexes and method to produce them |
Also Published As
Publication number | Publication date |
---|---|
ES2123432B1 (en) | 1999-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0943331A3 (en) | Formulations containing oxaliplatin | |
WO1998029110A3 (en) | Formulation and method for treating neoplasms by inhalation | |
PL317105A1 (en) | Compositions containing dna and p53 damaging agents | |
CA2263379A1 (en) | Method for iron delivery to a patient by transfer from dialysate | |
CA2173457A1 (en) | Use of 5-alpha reductase inhibitorsand compositions for treating androg enic alopecia | |
PL343164A1 (en) | An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition | |
DE69736067D1 (en) | Neue cryptophycin-derivate als antineoplastika | |
IL134259A0 (en) | Use of physiologically acceptable vanadium compounds, salts and complexes | |
WO1999022722A3 (en) | Use of macrolides for the treatment of cancer and macular degeneration | |
EP2258702A3 (en) | Purified compositions of 10-Propargyl-10-Deazaaminopterin and method of using same in the treatment of tumors | |
HU895608D0 (en) | Process for the preparation of chelates containing ortho ligating functional group and complexes thereof | |
HUT56849A (en) | Process for producing antibiotic complexes and chelates and pharmaceutical compositions comprising such active ingredient | |
ZA837857B (en) | Platinum-diamine complexes,a process for the preparation thereof and a process for the preparation of a medical composition using such a complex for the treatment of cancer | |
ES2123432A1 (en) | Formulation for oral delivery of iron complexes - comprises water-soluble adduct comprising polyhydroxylated trivalent iron complex with soluble albumin | |
EP1545479A4 (en) | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors | |
AU5170499A (en) | Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis | |
AU2162700A (en) | Supramolecular complexes containing therapeutic agents | |
EP0281070A3 (en) | Pharmaceutical composition for the treatment of cancer | |
WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
IL131959A0 (en) | Pharmaceutical combined preparations containing erythropoietin and iron preparations | |
WO1999011256A8 (en) | L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof | |
ES2188336A1 (en) | Soluble albumin adducts with polyhydroxilated complexes (polyalcoholic) of trivalent iron, method for obtaining them and pharmaceutical and dietetic preparations that contain them. | |
WO1997033620A3 (en) | Compounds for treating tumours | |
WO1994020115A3 (en) | Hyaluronic acid used as a cancer treatment | |
WO1993020852A3 (en) | Macrocyclic chelating agents, chelates and conjugates thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 19990101 Kind code of ref document: A1 Effective date: 19990101 |
|
FD2A | Announcement of lapse in spain |
Effective date: 20170126 |